Yescarta is the Second gene therapy approved by the FDA, targeting blood cancer

U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults.

The Food and Drug Administration allowed sales of the treatment from Kite Pharma. It uses the same technology, called CAR-T, as the first gene therapy approved in the U.S. in August, a treatment for childhood leukemia from Novartis Pharmaceuticals.

"In just several decades, gene therapy has gone from being a promising concept to a practical solution to deadly and largely untreatable forms of cancer," FDA Commissioner Dr. Scott Gottlieb said in a statement.

The full article is available at the following link: http://abcnews.go.com/Technology/wireStory/us-regulators-approve-2nd-gene-therapy-blood-cancer-50575153